Pharmaceuticals
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...
2021-08-31 18:00
3921
Harbour BioMed Reports 2021 Interim Results
CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...
2021-08-31 13:47
4243
InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723
BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Food and Drug Administration (FDA) for starting phase I cli...
2021-08-31 08:30
3038
Viva Biotech Announced 2021 Interim Results
Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rderBacklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: * Revenue amounted to RMB1,026.5 million, representing a year-on-year (YoY) increase of approximately 419...
2021-08-31 01:32
5742
Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix
SEOUL, South Korea, Aug. 30, 2021 /PRNewswire/ -- CancerRop (180400), a company specializing in precision medicine and molecular diagnostics, announced a jump start in the global vaccine hub for COVID-19 mRNA (messenger ribonucleic acid) with Hanmi Science through20 billion won worth of investmen...
2021-08-30 23:00
3821
Everest Medicines Announces Half-Year 2021 Interim Results
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines
2021-08-30 22:15
5720
Everest Medicines Announces Up to HK$100 million Share Repurchase Program
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-08-30 22:03
4888
I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...
2021-08-30 20:00
2167
Alphamab Oncology Reports 2021 Interim Results and Business Highlights
SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2021 ...
2021-08-30 10:51
4711
GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science
SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...
2021-08-30 10:00
2442
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021
SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2021-08-30 08:00
4374
Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that the former President and Head of Research & Clinical Development, Dr.Henri Nico Doods, will serve as the company's Chief Executive Officer. Dr...
2021-08-30 08:00
8220
InnoCare Releases 2021 Half Year Results and Business Highlights
BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended onJune 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On the fo...
2021-08-29 19:49
5213
IONOVA Life Science Announces New Financing Round of USD $100 Million
SHENZHEN, China, Aug. 27, 2021 /PRNewswire/ -- On August 27, 2021, Shenzhen IONOVA Life Science Co., Ltd. ("IONOVA" or "the company"), a clinical-stage biotechnology company located in theGuangdong-Hong Kong-Macao Greater Bay Area ofChina, announced completion of a new financing round of USD $100...
2021-08-27 22:00
3399
Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer
SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) ofChina has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate...
2021-08-27 11:20
1954
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
SAN FRANCISCO and SUZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-08-27 08:00
5753
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of$50 million, with Lilly Asia Ventures (LAV) as lead ...
2021-08-27 08:00
6288
JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions
Population–based cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs. PLYMOUTH MEETING, Pa., Aug. 27, 2021 /PRNewswire/ -- Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer...
2021-08-27 03:30
2198
Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases
SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, and4B Technologies Co., Ltd. ("4B Technologies"), a leading end-to-end innovative biopharmaceutical company focusing on nervous system diseases, signed...
2021-08-27 03:22
32002
PharmaBlock Announces the Appointment of Dr. Xudong Wei as Senior Vice President to Lead and Enhance Small Molecule CDMO Services
NANJING, China, Aug. 26, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Xudong Wei as Senior Vice President and Head of CDMO Business to enhance s...
2021-08-26 23:00
4260
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
PT Telkom Indonesia (Persero) Tbk 2025 Annual Report on Form 20-F
2026-05-16 00:26
7877
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
2026-05-16 11:14
5749
Lepro Introduces STV1, a TV Backlight That Combines Screen Sync, AI Lighting, and Easier Setup
2026-05-16 00:00
5622
NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial
2026-05-18 21:29
5180
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5126
